Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About

Johnson & Johnson is experiencing strong performance with stock up 28% YTD, driven by FDA clearance for its Ottava surgical robot, 64 consecutive years of dividend increases, and $100 billion revenue target. Most significantly, the company reached a proposed $5.5 billion settlement to resolve thousands of talc-related lawsuits, potentially eliminating a major legal risk. The company maintains resilience through diversified products and continues innovation with new drug approvals.

07/30/2026, 4:15 PM • The Motley Fool

Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer

Bristol Myers Squibb's 4.1% dividend yield is sustainable in the near term, with earnings and free cash flow covering the payout more than twice over. However, the company faces a significant patent cliff as key drugs like Eliquis and Opdivo lose exclusivity by 2028, threatening roughly half of total revenue. While the dividend appears safe for now, investors should monitor how management navigates these challenges, potentially through slower dividend growth.

07/24/2026, 4:30 PM • The Motley Fool

Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight

The molecular glues market is experiencing significant growth with over 80 active players developing 90+ pipeline candidates. Key companies including Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, and others are advancing promising molecular glue degraders across oncology, immunology, and neurodegenerative diseases. Recent developments include FDA Breakthrough Therapy Designation for Daraxonrasib and multiple clinical trial initiations, positioning molecular glues as a promising therapeutic strategy for previously undruggable proteins.

07/23/2026, 1:00 PM • GlobeNewswire

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.

07/22/2026, 5:30 AM • The Motley Fool

Prediction: U.S. Value Stocks Will Outperform for 10 Years. Which ETFs Should You Buy?

Vanguard research forecasts that U.S. value stocks and small-cap stocks will outperform growth stocks over the next 10 years. The article compares two Vanguard ETFs for value stock exposure: the Vanguard Small-Cap Value ETF (VBR), a passively managed fund with ultra-low fees, and the Vanguard U.S. Value Factor ETF (VFVA), an actively managed alternative with broader market-cap exposure. Both funds have recently outperformed the S&P 500 and Nasdaq-100.

07/21/2026, 2:30 PM • The Motley Fool

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire

BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt

BioNTech will release second quarter 2026 financial results on August 4, 2026, followed by a conference call. The company will showcase progress across its late-stage oncology pipeline at ASCO 2026, including data on its PD-L1xVEGF-A bispecific pumitamig developed with Bristol Myers Squibb, which demonstrated encouraging efficacy in non-small cell lung cancer patients.

07/21/2026, 6:45 AM • GlobeNewswire

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

BioNTech will announce its second quarter 2026 financial results on August 4, 2026, followed by a conference call. The company will showcase progress across its late-stage oncology pipeline at ASCO 2026, including encouraging efficacy data from the ROSETTA Lung-02 trial for its PD-L1xVEGF-A bispecific pumitamig in non-small cell lung cancer patients, developed in partnership with Bristol Myers Squibb.

07/21/2026, 6:45 AM • GlobeNewswire

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

The article compares two healthcare ETFs: IHE (U.S. Pharmaceuticals) and IXJ (Global Healthcare). IHE offers concentrated exposure to 56 U.S. pharmaceutical companies with higher recent returns (50.30% 1-yr), but carries significant concentration risk with its top two holdings (J&J and Eli Lilly) comprising 43% of the portfolio. IXJ provides broader diversification across 110 international healthcare companies including medical devices and services, with lower concentration risk but more modest recent returns (18.20% 1-yr). The article suggests IXJ is better for diversification-focused investors, while IHE's outperformance is largely driven by GLP-1 weight-loss drug success.

07/18/2026, 8:16 PM • The Motley Fool

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

07/13/2026, 1:00 PM • GlobeNewswire

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now

Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (8.2x and 9x forward earnings), they are recommended as potential buys for dividend investors with $1,000 to deploy.

07/07/2026, 6:30 PM • The Motley Fool

Exploring the Cancer Metabolism-Based Therapeutics Market: Key Drivers and Challenges to $26.3 Billion Growth

The cancer metabolism-based therapeutics market is projected to grow from $3.7 billion in 2026 to $26.3 billion by 2035, driven by precision medicine approaches and rising cancer prevalence. The market includes approximately 250 therapeutic programs targeting cancer metabolism vulnerabilities, with North America expected to hold over 45% market share. Key challenges include metabolic pathway complexity and cancer cell plasticity, while strategic collaborations are accelerating development.

07/03/2026, 7:54 AM • GlobeNewswire

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two major healthcare stocks: Bristol Myers Squibb (BMY), a specialized biopharmaceutical company focused on oncology and immunology, and Johnson & Johnson (JNJ), a diversified healthcare giant with innovative medicine and medical device segments. While BMY trades at a significant valuation discount with a higher dividend yield (4.51%), JNJ is recommended as the better 2026 buy due to its stronger growth prospects, superior margins (28.5% vs 14.6%), robust free cash flow ($20B vs $12.8B), and more diversified revenue streams with 28 billion-dollar products. Both face patent cliff challenges and government price negotiation pressures.

06/26/2026, 11:30 AM • The Motley Fool

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire